Abstract
Metastatic castration-resistant prostate cancer (mCRPC) is universally incurable and represents an area of substantial unmet medical need. Novel targets and therapeutic strategies have emerged based on an improved understanding of the crosstalk between prostate cancer cells and the bone microenvironment. A wide variety of signaling systems including the RANKL/RANK/OPG, IGF-I, FGF and Wnt:DKK-1 pathways can be targeted to suppress tumor growth and treatment resistance. Antisurvival factor therapy can increase the efficacy of standard antineoplastic regimens by targeting biologic molecules acting as “survival factors” within the bone microenvironment. Novel agents can also be used to mobilize the host immune system to attack prostate cancer cells. Clinical testing of these therapeutic approaches has produced encouraging objective clinical responses in subsets of patients with mCRPC. The present review summarizes data regarding the emerging strategies used to target the bone microenvironment in mCRPC.
Keywords: Bone metastasis, castration-resistant prostate cancer, tumor microenvironment.
Current Drug Targets
Title:Targeting the Bone Microenvironment in Metastatic Castration-Resistant Prostate Cancer
Volume: 17 Issue: 3
Author(s): Pavlos Msaouel, Jose Nahun Galeas, Alejandro Recio Boiles, Ramiro Rancier Ruiz and Michael Koutsilieris
Affiliation:
Keywords: Bone metastasis, castration-resistant prostate cancer, tumor microenvironment.
Abstract: Metastatic castration-resistant prostate cancer (mCRPC) is universally incurable and represents an area of substantial unmet medical need. Novel targets and therapeutic strategies have emerged based on an improved understanding of the crosstalk between prostate cancer cells and the bone microenvironment. A wide variety of signaling systems including the RANKL/RANK/OPG, IGF-I, FGF and Wnt:DKK-1 pathways can be targeted to suppress tumor growth and treatment resistance. Antisurvival factor therapy can increase the efficacy of standard antineoplastic regimens by targeting biologic molecules acting as “survival factors” within the bone microenvironment. Novel agents can also be used to mobilize the host immune system to attack prostate cancer cells. Clinical testing of these therapeutic approaches has produced encouraging objective clinical responses in subsets of patients with mCRPC. The present review summarizes data regarding the emerging strategies used to target the bone microenvironment in mCRPC.
Export Options
About this article
Cite this article as:
Msaouel Pavlos, Galeas Nahun Jose, Boiles Recio Alejandro, Ruiz Rancier Ramiro and Koutsilieris Michael, Targeting the Bone Microenvironment in Metastatic Castration-Resistant Prostate Cancer, Current Drug Targets 2016; 17 (3) . https://dx.doi.org/10.2174/1389450116666150420143932
DOI https://dx.doi.org/10.2174/1389450116666150420143932 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Gefitinib Targets EGFR Dimerization and ERK1/2 Phosphorylation to Inhibit Pleural Mesothelioma Cell Proliferation
Current Cancer Drug Targets Application of Nanotechnology in the Treatment and Diagnosis of Gastrointestinal Cancers: Review of Recent Patents
Recent Patents on Anti-Cancer Drug Discovery Abnormal Signal Transduction via Over-expression of Pim-1 Regulated Senescence, Cell Cycle, Apoptosis and Metastatic Invasion: Novel Anticancer Targets and Their Potent Inhibitors from Marine Sources
Current Signal Transduction Therapy Proteomic Analysis of Glioma Chemoresistance
Current Neuropharmacology Cetuximab, A Chimeric Anti-Epidermal Growth Factor Receptor Monoclonal Antibody, in Colorectal Cancer Treatment
Current Cancer Therapy Reviews Synthesis and Evaluation of a Novel Gene Reporter Molecule: Detection of b-galactosidase Activity Using 19F NMR of a Fluorinated Vitamin B6 Conjugate+
Medicinal Chemistry Computer-Aided Drug Design Applied to Secondary Metabolites as Anticancer Agents
Current Topics in Medicinal Chemistry Metabolic Basis of Sporadic Alzeimer’s Disease. Role of Hormones Related to Energy Metabolism
Current Pharmaceutical Design Biocombinatorial Selection of Carbohydrate Binding Agents of Therapeutic Significance
Current Drug Discovery Technologies The Biological Functions of NF-κB1 (p ) and its Potential as an Anti-Cancer Target
Current Cancer Drug Targets The Control of Cell Cycle in Mouse Primordial Germ Cells: Old and New Players
Current Pharmaceutical Design Therapeutic Boosting of the Immune Response: Turning to CD14 for Help
Current Pharmaceutical Biotechnology Rock1 & 2 Perform Overlapping and Unique Roles in Angiogenesis and Angiosarcoma Tumor Progression
Current Molecular Medicine The Leptin System: A Potential Target for Sepsis Induced Immune Suppression
Endocrine, Metabolic & Immune Disorders - Drug Targets Prostate Cancer Prevention in the Developing World - What are we Waiting for?
Current Pharmacogenomics and Personalized Medicine A Critical Systematic Review of Recent Clinical Trials Comparing Open Retropubic, Laparoscopic and Robot-Assisted Laparoscopic Radical Prostatectomy
Reviews on Recent Clinical Trials Natural Phenolic Compounds as Cardiovascular Therapeutics: Potential Role of their Antiinflammatory Effects
Current Vascular Pharmacology Quantitative Structure-activity Relationships of Imidazole-containing Farnesyltransferase Inhibitors Using Different Chemometric Methods
Medicinal Chemistry Physcion and Physcion 8-O-β-D-glucopyranoside: Natural Anthraquinones with Potential Anticancer Activities
Current Drug Targets Focused Microarray Analysis: Characterization of Phenomes by Gene Expression Profiling
Current Pharmacogenomics